NCT06699810RecruitingPhase 4
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 19 Nov 2024
- Start date
- 23 Jan 2025
- Primary completion date
- Jan 2027
- Lead sponsor
- Emory University
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT06699810
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 12
- From 23 Jan 2025 to the primary completion date, Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of diabetes \> 90 days before the presentation of DKA
Other illness
- Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
Lab values
- Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
- Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
Other
- Pregnant
- Unable to give consent
Who the study is looking for
- Provide informed consent
- Have a BMI ≥ 28 kg/m2
- Be of African American ancestry
- Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital Midtown Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| Grady Health System Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.